MX2022015229A - Mejora de la tolerabilidad de anticuerpos asociada con la administracion intravenosa. - Google Patents
Mejora de la tolerabilidad de anticuerpos asociada con la administracion intravenosa.Info
- Publication number
- MX2022015229A MX2022015229A MX2022015229A MX2022015229A MX2022015229A MX 2022015229 A MX2022015229 A MX 2022015229A MX 2022015229 A MX2022015229 A MX 2022015229A MX 2022015229 A MX2022015229 A MX 2022015229A MX 2022015229 A MX2022015229 A MX 2022015229A
- Authority
- MX
- Mexico
- Prior art keywords
- administration
- antibody
- intravenous
- mice
- isolation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20178287.7A EP3919077A1 (en) | 2020-06-04 | 2020-06-04 | Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies |
| EP21163703 | 2021-03-19 | ||
| PCT/EP2021/065014 WO2021245238A1 (en) | 2020-06-04 | 2021-06-04 | Improving antibody tolerability associated with intravenous administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015229A true MX2022015229A (es) | 2023-02-09 |
Family
ID=76217874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015229A MX2022015229A (es) | 2020-06-04 | 2021-06-04 | Mejora de la tolerabilidad de anticuerpos asociada con la administracion intravenosa. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20230322933A1 (https=) |
| EP (2) | EP4161574A1 (https=) |
| JP (1) | JP2023527926A (https=) |
| KR (1) | KR20230038180A (https=) |
| CN (1) | CN116322767A (https=) |
| AU (1) | AU2021286202A1 (https=) |
| BR (1) | BR112022024745A2 (https=) |
| CA (1) | CA3185020A1 (https=) |
| IL (1) | IL298757A (https=) |
| MX (1) | MX2022015229A (https=) |
| TW (3) | TW202210103A (https=) |
| WO (3) | WO2021245238A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202342057A (zh) * | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2196002T3 (es) | 1991-07-25 | 2003-12-16 | Idec Pharma Corp | Anticuerpos recombinantes para terapia humana. |
| US8187593B2 (en) * | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| EP2490715A4 (en) * | 2009-10-21 | 2013-06-26 | Immunogen Inc | NEW DOSAGE ADMINISTRATION REGIMEN AND METHOD OF TREATMENT |
| GB201013989D0 (en) * | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| GB2526139A (en) | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
| AU2016378573A1 (en) * | 2015-12-22 | 2018-07-19 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-CD20/anti-CD3 antibodies to treat acute lymphoblastic leukemia |
| WO2019081983A1 (en) * | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
| EP3737698A2 (en) | 2018-01-10 | 2020-11-18 | BioInvent International AB | Novel combination and use of antibodies |
| MX2021001058A (es) | 2018-08-16 | 2021-04-12 | Genmab As | Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de un cancer. |
| CA3110513A1 (en) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
-
2021
- 2021-06-04 WO PCT/EP2021/065014 patent/WO2021245238A1/en not_active Ceased
- 2021-06-04 EP EP21729338.0A patent/EP4161574A1/en active Pending
- 2021-06-04 TW TW110120463A patent/TW202210103A/zh unknown
- 2021-06-04 US US18/008,134 patent/US20230322933A1/en active Pending
- 2021-06-04 WO PCT/EP2021/065013 patent/WO2021245237A1/en not_active Ceased
- 2021-06-04 EP EP21729337.2A patent/EP4161573A1/en active Pending
- 2021-06-04 TW TW110120464A patent/TW202210104A/zh unknown
- 2021-06-04 WO PCT/EP2021/065005 patent/WO2021245233A1/en not_active Ceased
- 2021-06-04 CA CA3185020A patent/CA3185020A1/en active Pending
- 2021-06-04 KR KR1020237000393A patent/KR20230038180A/ko active Pending
- 2021-06-04 TW TW110120461A patent/TW202210102A/zh unknown
- 2021-06-04 MX MX2022015229A patent/MX2022015229A/es unknown
- 2021-06-04 AU AU2021286202A patent/AU2021286202A1/en active Pending
- 2021-06-04 US US18/008,141 patent/US20240301070A1/en active Pending
- 2021-06-04 JP JP2022574537A patent/JP2023527926A/ja active Pending
- 2021-06-04 BR BR112022024745A patent/BR112022024745A2/pt unknown
- 2021-06-04 CN CN202180058034.4A patent/CN116322767A/zh active Pending
- 2021-06-04 IL IL298757A patent/IL298757A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202210103A (zh) | 2022-03-16 |
| CA3185020A1 (en) | 2021-12-09 |
| JP2023527926A (ja) | 2023-06-30 |
| WO2021245237A1 (en) | 2021-12-09 |
| US20240301070A1 (en) | 2024-09-12 |
| AU2021286202A1 (en) | 2023-01-19 |
| US20230322933A1 (en) | 2023-10-12 |
| WO2021245238A1 (en) | 2021-12-09 |
| EP4161574A1 (en) | 2023-04-12 |
| TW202210102A (zh) | 2022-03-16 |
| WO2021245238A9 (en) | 2023-02-02 |
| KR20230038180A (ko) | 2023-03-17 |
| IL298757A (en) | 2023-02-01 |
| TW202210104A (zh) | 2022-03-16 |
| BR112022024745A2 (pt) | 2023-03-07 |
| EP4161573A1 (en) | 2023-04-12 |
| CN116322767A (zh) | 2023-06-23 |
| WO2021245233A1 (en) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691347A2 (ru) | Терапия глатирамером ацетатом с низкой кратностью | |
| Schlesinger | Canakinumab in gout | |
| Riedl et al. | Prospective, systematically recorded mycophenolate safety data in Graves’ orbitopathy | |
| MX2022015229A (es) | Mejora de la tolerabilidad de anticuerpos asociada con la administracion intravenosa. | |
| SA522432668B1 (ar) | طرق لعلاج سرطان الرئة للخلايا الصغيرة بصيغ من لوربينيكتيدين | |
| Van Hiele | l-5-Hydroxytryptophan in depression: the first substitution therapy in psychiatry? The treatment of 99 out-patients with ‘therapy-resistant’depressions | |
| Sebastian et al. | Current pharmacologic options and emerging therapeutic approaches for the management of ulcerative colitis: a narrative review | |
| BR112022013264A2 (pt) | Combinação de formas de dosagem oral sólida de decitabina e cedazuridina | |
| Mancuso et al. | NXT007 prophylaxis in people with hemophilia A with or without FVIII inhibitors: A global Phase I/II multiple-ascending-dose study | |
| American et al. | Vardenafil provides reliable efficacy over time in men with erectile dysfunction | |
| HRP20150889T1 (hr) | Postupci za lijeäśenje adhezivnog kapsulitisa | |
| Pongruangporn et al. | Vancomycin‐associated leukocytoclastic vasculitis | |
| BR112021016795A8 (pt) | Administração de inibidor de enzima de ativação de sumo e inibidores de checkpoint | |
| Musick et al. | P276 Long-term safety, and efficacy of subcutaneous Efgartigimod PH20 in patients with generalized myasthenia gravis: interim results of ADAPT-SC+ | |
| BR112022023137A2 (pt) | Administração de inibidor de enzima de ativação de sumo e anticorpos anti-cd38 | |
| Bonkovsky et al. | S1170 Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyria: 24-Month Interim Analysis of the Phase 3 ENVISION Randomized Clinical Trial | |
| Ashcraft et al. | P277 Long-term safety, tolerability, and efficacy of Efgartigimod in patients with Generalized Myasthenia Gravis: concluding analyses from the ADAPT+ study | |
| Yurttas et al. | POS1381 biologic treatment of adult-onset Still's disease: A single center experience | |
| Cassiman et al. | S1171 EXPLORE Part B: A Prospective, International, Long-Term Natural History Study of Patients With Acute Hepatic Porphyria With Recurrent Symptoms | |
| Grierson | From Beşiktaş to Bahâriye: The Life and Times of Hüseyin Fahreddin el-Mevlevî | |
| Sanchorawala et al. | Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): analysis of SWOG trial S0115 | |
| Yubin et al. | Esketamine Improves Working Memory Impairment in Neuropathic Mice Through Hippocampal BDNF-TrkB Pathway | |
| Lanzillotta et al. | POS1382 RITUXIMAB FOR INDUCTION OF REMISSION IN TYPE 1 AUTOIMMUNE PANCREATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS | |
| Robbins | Oral Calcitonin Gene-Related Peptide Antagonist for Migraine Prevention | |
| Reifenschweiler | Pethidine abuse |